Join our daily newsletter At The Bell to receive exclusive market insights
- Alterity Therapeutics (ATH) has appointed Dr David Stamler as CEO, effective immediately
- Dr Stamler has been with the company since June 2017, previously serving as Chief Medical Officer and Senior Vice President Clinical Development
- He has significant experience in pharmaceutical development and commercialisation, including three new drug application approvals with the U.S. Food and Drug Administration (FDA)
- Dr Stamler will replace former CEO Geoffrey Kempler, who will continue as Non-Executive Chairman
- Alterity is up 3.23 per cent on the market and shares are currently trading at 3.2 cents
Alterity Therapeutics (ATH) has appointed Dr David Stamler as CEO, effective immediately.
He will replace former CEO Geoffrey Kempler, who will continue as Non-Executive Chairman. Additionally, Geoffrey will be engaged in a consulting capacity.
“It’s been a great privilege to work towards improving the lives of millions of people suffering from neurodegenerative diseases,” Geoffrey said.
“I am delighted that David Stamler, who joined Alterity over three years ago, has agreed to succeed me and assume the role of CEO. David is enormously talented, and I look forward to continuing to work with him as we continue to advance our treatments for Parkinsonian diseases,” he added.
Dr Stamler has been with the company since June 2017, previously serving as Chief Medical Officer and Senior Vice President Clinical Development.
He has significant experience in pharmaceutical development and commercialisation, including three new drug application approvals with the U.S. Food and Drug Administration (FDA).
“When I first joined Alterity, I was impressed and excited at the novel technology that underpins our portfolio of potential treatments for neurodegenerative disease and since then have been pleased with the progress we’ve made,” Dr Stamler commented.
“We are at an important juncture as we move into later-stage clinical trials for our lead compound ATH434 and I look forward to now leading the business as CEO and advancing our commercialisation program,” he added.
Alterity is up 3.23 per cent on the market and shares are trading at 3.2 cents at 12:54 pm AEDT.
